Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Yearly performance of total market index funds provides a broad view of winners and laggards. Use these insights to adjust your exposure today.
28,320 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Discover how nyxoah (nyxh) 2025 earnings could shape an investor's view of MedTech plays. This forward-looking analys...
IonQ delivers a standout Q1 and a fresh price-target outlook that signals potential triple-digit gains over the next ...
A new, concentrated fund is delivering outsized tech gains fueled by Nvidia, Micron and TSMC. The fund’s early-2026 s...
Roundhill's DRAM ETF, with a 49% Korea weighting, has surged but faces overnight gaps as half its holdings trade when...
The FHFA proposes an outcome-based Duty to Serve overhaul to push Fannie Mae and Freddie Mac toward stronger support ...
Applied Materials just ripped higher again, sparking a profit-taking debate as the stock taps fresh highs. This repor...
SoFi shareholders have faced a tough year, but a pair of upbeat bank results offers a new tailwind. This article brea...
Papa John's approaches 2025 with a focus on digital growth, franchise economics, and international expansion. This ar...
The vnet 2025 earnings call laid out a clear path for growth and profitability in a competitive cloud market. This an...
OpenAI's ongoing losses highlight the high-cost path of AI leadership. This article explains why two blue-chip AI sto...
Markets watch the debt path as deficits and entitlement costs rise. A budget watchdog warns that the current calm cou...